• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.用于宫颈癌免疫治疗的表达人乳头瘤病毒蛋白的重组痘苗病毒的构建与特性分析
Vaccine. 1996 Nov;14(16):1485-94. doi: 10.1016/s0264-410x(96)00117-x.
2
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.表达修饰的人乳头瘤病毒（HPV）-16和HPV-18 E6及E7基因的重组痘苗病毒TA-HPV在晚期宫颈癌女性患者中的安全性和免疫原性。
Clin Cancer Res. 2002 Dec;8(12):3676-85.
3
Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector.在活痘苗病毒载体中对人乳头瘤病毒16型E6基因的免疫反应
J Gen Virol. 1994 Jan;75 ( Pt 1):157-64. doi: 10.1099/0022-1317-75-1-157.
4
Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.用表达人乳头瘤病毒 16 型和 18 型双价 E7E6 融合蛋白的重组痘苗病毒在小鼠和恒河猴中进行免疫原性研究。
Virol J. 2011 Jun 15;8:302. doi: 10.1186/1743-422X-8-302.
5
[Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].共表达人乳头瘤病毒16型L1/L2/E6/E7蛋白的非复制型重组痘苗病毒的构建与鉴定
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):240-3.
6
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.一种编码人乳头瘤病毒16型和18型E6和E7蛋白的重组痘苗病毒，作为宫颈癌的免疫疗法。
Lancet. 1996 Jun 1;347(9014):1523-7. doi: 10.1016/s0140-6736(96)90674-1.
7
Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.在小鼠肿瘤模型中，甲病毒介导的针对16型人乳头瘤病毒抗原免疫的卓越治疗效果：免疫途径的影响
Antivir Ther. 2004 Oct;9(5):733-42.
8
Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.两种表达人乳头瘤病毒16型（HPV - 16）E7不同分子形式的单核细胞增生李斯特菌疫苗载体诱导出性质不同的T细胞免疫，这与其诱导由HPV - 16永生化的已建立肿瘤消退的能力相关。
J Immunol. 2001 Dec 1;167(11):6471-9. doi: 10.4049/jimmunol.167.11.6471.
9
Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.宫颈癌的基因免疫：用表达人乳头瘤病毒16型E6和E7的重组甲病毒载体诱导细胞毒性T淋巴细胞活性
Gene Ther. 2000 Nov;7(21):1859-66. doi: 10.1038/sj.gt.3301257.
10
Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.通过给予包含牛分枝杆菌卡介苗（BCG）热休克蛋白65（hsp65）和人乳头瘤病毒16型（HPV16）E7的融合蛋白对表达HPV16 E7的肿瘤进行免疫治疗。
Clin Exp Immunol. 2000 Aug;121(2):216-25. doi: 10.1046/j.1365-2249.2000.01293.x.

引用本文的文献

1
Ad-E6/7-HR vaccine improves the prophylactic and therapeutic efficacy in HPV-associated cancers.腺病毒 E6/E7 重组疫苗可提高人乳头瘤病毒相关癌症的预防和治疗效果。
Clin Transl Med. 2025 Apr;15(4):e70305. doi: 10.1002/ctm2.70305.
2
Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study.在一项临床前小鼠研究中，通过黏膜重组腺病毒5型治疗性疫苗消除人乳头瘤病毒16阳性肿瘤。
Vaccines (Basel). 2024 Aug 23;12(9):955. doi: 10.3390/vaccines12090955.
3
The Interaction of Human Papillomavirus Infection and Prostaglandin E Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics.人乳头瘤病毒感染与前列腺素 E 信号在癌症发生中的相互作用：以宫颈癌治疗为重点。
Cells. 2022 Aug 15;11(16):2528. doi: 10.3390/cells11162528.
4
Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.针对人乳头瘤病毒 16（HPV16）和 HPV18 的 E6 和 E7 蛋白的 DNA 疫苗的开发，用于与重组痘苗增强和 PD-1 抗体联合免疫治疗。
mBio. 2021 Jan 19;12(1):e03224-20. doi: 10.1128/mBio.03224-20.
5
Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis.基于基因工程乳酸杆菌的 HPV 疫苗 20 年研究：肠道-阴道轴概述。
Cell Mol Life Sci. 2021 Feb;78(4):1191-1206. doi: 10.1007/s00018-020-03652-2. Epub 2020 Sep 26.
6
Targeting Head and Neck Cancer by Vaccination.通过疫苗接种靶向头颈部癌症。
Front Immunol. 2018 Apr 23;9:830. doi: 10.3389/fimmu.2018.00830. eCollection 2018.
7
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.尝试攻克癌症；溶瘤病毒介导的抗癌疫苗接种策略
Biomedicines. 2017 Jan 4;5(1):3. doi: 10.3390/biomedicines5010003.
8
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.瘤内注射治疗性 HPV 痘苗疫苗联合顺铂可增强 HPV 特异性抗肿瘤作用。
Cancer Immunol Immunother. 2013 Jul;62(7):1175-85. doi: 10.1007/s00262-013-1421-y. Epub 2013 Apr 25.
9
Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers.预防性和治疗性 HPV 疫苗与宫颈癌。
Iran J Basic Med Sci. 2012 Jan;15(1):585-601.
10
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.针对 HPV16/18 的免疫疗法可产生强烈的 TH1 和细胞毒性细胞免疫应答。
Sci Transl Med. 2012 Oct 10;4(155):155ra138. doi: 10.1126/scitranslmed.3004414.

本文引用的文献

1
Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.肿瘤浸润淋巴细胞对人肾细胞癌的肿瘤特异性裂解。I. HLA-A2 限制的自体和同种异体肿瘤细胞系识别
J Immunol. 1993 Oct 15;151(8):4209-20.
2
Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions.人乳头瘤病毒癌基因表达在宫颈癌细胞中的可逆性抑制：对细胞表型及E6-p53和E7-pRB相互作用的影响
J Virol. 1994 May;68(5):2811-21. doi: 10.1128/JVI.68.5.2811-2821.1994.
3
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.与体内肿瘤排斥相关的肿瘤浸润淋巴细胞所识别的一种人类黑色素瘤抗原的鉴定。
Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62. doi: 10.1073/pnas.91.14.6458.
4
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.使用基因修饰的病毒特异性T淋巴细胞来控制爱泼斯坦-巴尔病毒相关的淋巴增殖。
Lancet. 1995 Jan 7;345(8941):9-13. doi: 10.1016/s0140-6736(95)91150-2.
5
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.接种含细胞毒性T淋巴细胞表位的肽可预防由16型人乳头瘤病毒转化细胞诱导的肿瘤。
Eur J Immunol. 1993 Sep;23(9):2242-9. doi: 10.1002/eji.1830230929.
6
Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.人乳头瘤病毒E7蛋白细胞毒性T淋巴细胞表位图谱所揭示的预测基序的局限性
Int Immunol. 1994 Feb;6(2):289-96. doi: 10.1093/intimm/6.2.289.
7
Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies.使用抗肽抗体扫描人乳头瘤病毒16型E6和E7癌蛋白的结构与抗原性。
Oncogene. 1994 Feb;9(2):635-45.
8
Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene.痘苗病毒早期基因多个起始和终止位点附近的独特核苷酸序列。
Cell. 1981 Sep;25(3):805-13. doi: 10.1016/0092-8674(81)90188-4.
9
Isolation of a transforming sequence from a human bladder carcinoma cell line.从人膀胱癌细胞系中分离出一个转化序列。
Cell. 1982 May;29(1):161-9. doi: 10.1016/0092-8674(82)90100-3.
10
Complications of smallpox vaccination, 1968.天花疫苗接种的并发症，1968年
N Engl J Med. 1969 Nov 27;281(22):1201-8. doi: 10.1056/NEJM196911272812201.

用于宫颈癌免疫治疗的表达人乳头瘤病毒蛋白的重组痘苗病毒的构建与特性分析

Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.

作者信息

Boursnell M E, Rutherford E, Hickling J K, Rollinson E A, Munro A J, Rolley N, McLean C S, Borysiewicz L K, Vousden K, Inglis S C

机构信息

Cantab Pharmaceuticals Research Ltd., Cambridge, UK.

出版信息

Vaccine. 1996 Nov;14(16):1485-94. doi: 10.1016/s0264-410x(96)00117-x.

DOI:10.1016/s0264-410x(96)00117-x
PMID:9014288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7130629/
Abstract

The presence and consistent expression of the genes encoding the human papillomavirus (HPV) E6 and E7 proteins in the great majority of cervical tumours presents the opportunity for an immunotherapeutic approach for control of the disease. This report describes the construction and characterisation of a recombinant vaccinia virus designed to express modified forms of the E6 and E7 proteins from HPV16 and HPV18, the viruses most commonly associated with cervical cancer. The recombinant virus (designated TA-HPV) was based on the Wyeth vaccine strain of vaccinia, and was shown to express the desired gene products. Studies in mice indicated that the recombinant virus was less neurovirulent than the parental virus and was capable of inducing an HPV-specific CTL response. This pre-clinical evaluation has provided a basis for the initiation of human trials in cervical cancer patients.

摘要

在绝大多数宫颈肿瘤中，编码人乳头瘤病毒（HPV）E6和E7蛋白的基因的存在及持续表达为通过免疫治疗方法控制该疾病提供了契机。本报告描述了一种重组痘苗病毒的构建及特性，该病毒旨在表达来自HPV16和HPV18的E6和E7蛋白的修饰形式，这两种病毒是最常与宫颈癌相关的病毒。重组病毒（命名为TA-HPV）基于惠氏痘苗疫苗株，且已证明其能表达所需的基因产物。对小鼠的研究表明，重组病毒的神经毒性低于亲本病毒，并且能够诱导HPV特异性CTL反应。这种临床前评估为启动针对宫颈癌患者的人体试验提供了依据。